spiperone has been researched along with Dermatitis, Contact in 2 studies
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.
Dermatitis, Contact: A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.
Excerpt | Relevance | Reference |
---|---|---|
"When spiperone was given subcutaneously at a dose of 30 or 150 mg/kg, 1 h after challenge with oxazolone, cutaneous contact hypersensitivity to this hapten was significantly diminished." | 1.28 | Inhibition of cutaneous contact hypersensitivity in the mouse with systemic or topical spiperone: topical application of spiperone produces local immunosuppression without inducing systemic neuroleptic effects. ( Arndt, KA; Chandrasekar, A; Galli, SJ; Sharpe, RJ; Wang, ZS, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Solinski, HJ | 1 |
Dranchak, P | 1 |
Oliphant, E | 1 |
Gu, X | 1 |
Earnest, TW | 1 |
Braisted, J | 1 |
Inglese, J | 1 |
Hoon, MA | 1 |
Sharpe, RJ | 1 |
Chandrasekar, A | 1 |
Arndt, KA | 1 |
Wang, ZS | 1 |
Galli, SJ | 1 |
2 other studies available for spiperone and Dermatitis, Contact
Article | Year |
---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Inhibition of cutaneous contact hypersensitivity in the mouse with systemic or topical spiperone: topical application of spiperone produces local immunosuppression without inducing systemic neuroleptic effects.
Topics: Administration, Topical; Animals; Dermatitis, Contact; Dopamine Antagonists; Drug Hypersensitivity; | 1992 |